The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
schalfenplanet: eh?
Rocquet ,
Phase 2 can use frozen samples- it needs to get through phase 2 to get to phase 3.
Oops plague not plaque lol
@avastar I speak from experience , we do have the best kit in the world when it comes from biological agents whether aerosol or airborne or just plaque.
But thank you for your thoughts
Schalf
"Think about this, if ODX are manufacturing the best test in the world then it will put them on the whole map on the world!"
Dude, that's not how business works. It's my belief that if they get the approvals they are currently seeking ODX will be maxed out producing and selling at higher margin their own Visitect test. And there are by now very many 'best in world' tests out there so take it with a pinch of salt and don't believe everything the pumpers and single stock fanatics on these bulletin boards say.
Ah yes Medusa that highly reputable name in medical diagnostics whos owners other ventures have been accused of modern slavery
@TWatcher we are the best in the world for testing, analysing and protecting against biological agents...
I am unsure why you continue to be so disruptive, tbh it's disturbing.
I think you need sometime out, you are embarrassing yourself fella.
I hope you get better soon schalf
rocquet - got it, you're also invested in AVCT. That's cool but just don't let it cloud your judgement as to what is best for ODX.
"Hello EU. Please forgive and forget the 10 years of acrimony during brexit and the fact that we couldn't wait to leave the EU. That was nothing to do with us Mon cheri. We'd like to sell you our antigen test for home use"
Isn't that the british made test that failed validation by the british government, whilst 25 other tests were approved, including a number of chinese "crap" tests ?". Why the hell would we want to buy something from outside the EU that even their own government failed "
"ummm...."
"Yeah, that's what i thought, we'll stick to the Roche that's made in Europe and the extremely popular Abbot test that's been CE-ed for europe since the beginning of the year for self-swabbing and asymptomatic testing. Both those tests were also passed by Porton down. Thanks for your call"
https://www.medicaldevice-network.com/news/abbott-test-ce-mark/
"I don't think there will be a single test - there'll be a few in the supply pipeline."
Amen to that. If there is one takeaway from the Innova fiasco it's don't put all eggs in one basket. Let ODX produce their own test, and others theirs.
Rocquet, that's a link to Avacta's website. Not an independent evaluation. I don't care whose test it is we make. One of Avacta's recent RNS's suggested they weren't even bothering with UK evaluation and were focused overseas. Have you got a link to show they are going for UK evaluation?
rocquet it is the best performing test in a small study from 1 site. This means that the data is very likely to be affected by bias. If you showed me a triple centre study/ group of independent studies with sensitivity as high as shown in the initial data i would concede that yes it is by far and away the best test. I also dislike that the name of the trial partner is not shared. Why would that info be withheld?
I don't know why it isn't Surescreen to be fair - they've obviously passed everything and are busy making tests, so in this emergency why aren't we just building their product? I've genuinely been stumped by this since they started manufacturing, and thought we were waiting for a next-gen better model to use after PD finally completed.
"I think it could be Surescreen."
I've said that for a while... I think they'll also potentially agree Mologic/Visitest. I don't think there will be a single test - there'll be a few in the supply pipeline.
I think it could be Surescreen. They are also part of the UK RTC. Doesn't look like the DHSC will fall on their sword. They will be forced to explain why they have approved a test with 78% sensitivity from Innova and not yet approved a test with between 94 and 98% sensitivity depending on ct values. Can't say I am not totally fed up with the UK authorities. Looks like MHRA were pressured into agreeing Innova due to their capacity. What a mess.
rocquet i have never seen anybody so confident about a products performance based upon a small study. As mentioned by others if AVCT is chosen it sets ODX back by months so id rather they crack on with the Visitect product elsewhere especially as it seems our own government wont do anything without their palms being greased.
And this makes it even clearer:
"The test is already CE marked for professional-use and the Company is targeting approval by the end of July to allow the test to be sold in Europe for home-use as well."
"Also RNS states CE marking for home use is being sought is that for UK or EU home use?"
The first line of the RNS of 8 June is fairly clear:
"Omega announces that it has begun the process of engagement with its European Notified Body seeking CE marking of the VISITECT® COVID-19 Antigen test, a rapid point-of-care diagnostic test for the detection of active COVID-19 infections as a self-test."
"We just make tests and we don't and shouldn't care whose test we make!"
Do you seriously believe that?!!
In case you didn't know Visitect is ODX's own brand. Yes the antigen test is developed by Mologic but IMO still likely to be much higher margin for ODX than if they are ordered to produce an AVCT or other third party test. Also it sounds like ODX are ready to start churning out Visitect thereby avoiding the several months technology transfer delay likely required to produce a new third party test.
As to the unshakable belief of some AVCT followers that their test is world beating, the recent SP reaction tells its own story. For what it's worth, Visitect is also described as best in class and that claim is based on a very thorough evaluation.
Doesn't the test need to go through porton down for home use in the UK? Happy to be corrected if Ive misunderstood this! That being the case I thought Avacta would encounter difficulties due to frozen samples being used?
Also RNS states CE marking for home use is being sought is that for UK or EU home use?
Rocquet,
I was just commenting that Avacta isn't on the list published today. ODX would be mad to be planning to manufacture a test that has yet to get approval considering the mologic saga. Do you have some links for any Avacta evaluations already preformed?
This is not an Avacta ramp but research to figure out what test ODX might manufacture.
I didn't see Avacta ob the list...
This is referring to the gov contract but it seems for some reason the gov have taken a step back. I assume they would still facilitate the licence but this does read more like omega are trying to figure out a test that will work for them, for the gov and the company with the IP.
A bit of a change as for some reason it now looks like ODX have an input to the test selection but from a very limited list. Is this due to the amount of time the gov have wasted and trying to let ODX choose the one that suits them best? I suspect we don't really want to do Surescreen in order to provide a risk reduction by having 2 tests.
@megatro: You would think that this was using the UK government half of the available capacity, otherwise why would we be needing the DHSC to facilitate these discussions.
The question being why discussions outside of the DHSC contract to supply, if the Sovereign test was on the near horizon
If we had spare "Non DHSC" capacity why on earth were we not having these discussions independently and a long time ago.
Or was there something in the contract that allowed use of the loaned machinery outside the govt contract ( think it might be subject to govt approval)